Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
This is a Phase II, multi-center, randomized, double-blind study comparing the safety and
 efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and
 skin structure infection.
The purpose of the study is to determine the efficacy of 2 dose regimens of BC-3781 versus
 the licensed medicinal product vancomycin over 5 to 14 days. The population in this study
 will be patients with an acute bacterial skin and skin structure infection (ABSSSI) and they
 will receive treatment with one of two doses of BC-3781 or vancomycin, a standard treatment
 for this condition.
Inclusion Criteria:

 -  Male or female patients > 18

 -  Documented acute bacterial skin and skin structure infection

 Exclusion Criteria:

 -  Uncomplicated skin and skin structure infection